A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
The primary objective of this study is to determine the recommended dose and evaluate the effect of KW‐6356 on motor symptoms in Parkinson's disease and the primary endpoint is the change from baseline in Movement disorder society‐unified Parkinson's disease rating scale(MDS‐UPDRS) partIII score between KW‐6356 and placebo in patients with Parkinson's disease on treatment with Levodopa‐containing preparations as an adjunctive therapy.
Epistemonikos ID: 3096b86b8407a1cfa2241b810f2c698fbb0e5a9f
First added on: May 21, 2024